Market Overview

Kleresca® Releases Unique Biophotonic Rosacea Treatment


Kleresca® Releases Unique Biophotonic Rosacea Treatment

PR Newswire

COPENHAGEN, Denmark, Aug. 23, 2018  /PRNewswire/ -- Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, today announced the release of a new treatment for rosacea.    

A new biophotonic treatment for rosacea is now available to patients through aesthetic clinics across 10 markets including Denmark, UK, France, Spain, Italy, Germany, Belgium, Norway, Australia and Switzerland.  

The treatment is based on Kleresca®'s unique and patented biophotonic technology which uses fluorescent light energy to stimulate the skin's own repair mechanisms through photobiomodulation. The treatment is non-invasive and generally perceived as comfortable even to rosacea patients with enhanced skin sensitivity.

"This is a great treatment to add to the Kleresca® product portfolio and it offers us potential in all the markets we serve. The rosacea treatment will bolster our profile in therapeutic aesthetics and further define our footprint in the market," said Mr. Mikkel Schoedt, General Manager of Kleresca®.

Benefits of Kleresca® Rosacea Treatment

While being gentle with high efficacy and safety, this in-clinic treatment offers patients the following benefits:

  • Reduces inflammation, reducing the presence of papules and pustules
  • Reduces erythema and blushing by improving microvascularisation
  • Reduces the overall stress level of the skin, thereby reducing the feeling of burning and stinging
  • Induces a healing response, improving the overall skin quality

Prevalence of rosacea

Rosacea appears to be quite common, although its prevalence depends on population characteristics (e.g. predominance of fair skin). Looking at the latest publications, rosacea affects 5,46% of the population worldwide, which equates to 414.960.000 people[1].

What is rosacea?

Rosacea is a chronic inflammatory skin disorder that affects primarily the central areas of the face (cheeks, nose, chin and central forehead). It often appears with periods of aggravations and remissions of its signs and symptoms. 

Main symptoms are redness, skin becoming easily flushed, sensitive skin, pimples and fine red vascular lines (telangiectasias). Depending on the subtype of rosacea, it can be also expressed as rhinophyma (enlarged nose) or eye problems (swollen, red eyelids and conjunctivitis). Kleresca® Rosacea Treatment is suitable for subtype 1-3 (excluding subtype expressed in eyes).

The Kleresca® biophotonic system uses fluorescent light energy to stimulate the skin's own biological processes and repair mechanisms. It has been available on the market since 2014. The company recently obtained own CE-mark on all its products.   


Nadia Vega Vasiljev
Global PR and Communication

This information was brought to you by Cision,c2593853

The following files are available for download:

Cision View original content:

SOURCE Kleresca

View Comments and Join the Discussion!